AI Terminal
HEMOGENYX PHARMACEUTICALS PLC
Share Issue/Capital Change • Feb 10, 2021
4938_rns_2021-02-10_a22a0c57-e2a9-4a73-b109-0fd8c225c524.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5292O
Hemogenyx Pharmaceuticals PLC
10 February 2021
10 February 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Allotment of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has allotted 7,741,935 new ordinary shares of £0.01 each in the Company ("Ordinary Shares") in settlement of an arrangement fee due to the arranger of the Financing Facility announced on 18 November 18 2020 and approved by the Company's shareholders on 6 January 2021, under which an initial draw down of £12,000,000 was made on 3 February 2021.
An application has been made to the London Stock Exchange Main Market and admission of the new Ordinary Shares to trading is expected on or around 11 February 2021 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.
Total Voting Rights
Following Admission of the new Ordinary Shares, the Company will have 441,378,190 Ordinary Shares of £0.01 each in issue with voting rights. The Company does not hold any shares in treasury. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | [email protected] |
| Peter Redmond, Director | [email protected] |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSEAXANEDDFEFA